These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37550217)

  • 1. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.
    Caravaca-Fontán F; Stevens K; Padrón M; Huerta A; Montomoli M; Villa J; González F; Vega C; López Mendoza M; Fernández L; Shabaka A; Rodríguez-Moreno A; Martín-Gómez A; Labrador PJ; Molina Andújar A; Prados Soler MC; Martín-Penagos L; Yerovi E; Medina Zahonero L; De La Flor JC; Mon C; Ibernon M; Rodríguez Gómez A; Miquel R; Sierra M; Mascarós V; Luzardo L; Papasotiriou M; Arroyo D; Verdalles Ú; Martínez-Miguel P; Ramírez-Guerrero G; Pampa-Saico S; Moral Berrio E; Canga JLP; Tarragón B; Fraile Gómez P; Regidor D; Relea J; Xipell M; Andrades Gómez C; Navarro M; Álvarez Á; Rivas B; Quintana LF; Gutiérrez E; Pérez-Valdivia MÁ; Odler B; Kronbichler A; Geddes C; Anders HJ; Floege J; Fernández-Juárez G; Praga M
    Nephrol Dial Transplant; 2024 Jan; 39(2):328-340. PubMed ID: 37550217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study.
    Cheung JTK; Yang A; Wu H; Lau ESH; Shi M; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
    Diabetes Res Clin Pract; 2023 Jan; 195():110203. PubMed ID: 36493912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.
    Otoda T; Sekine A; Uemoto R; Tsuji S; Hara T; Tamaki M; Yuasa T; Tamaki T; Matsuhisa M; Aihara KI
    Diabetes Ther; 2024 Jan; 15(1):127-143. PubMed ID: 37883001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Baseline Clinical Variables on SGLT2i's Antiproteinuric Effect in Diabetic Kidney Disease.
    Capelli I; Ribichini D; Provenzano M; Vetrano D; Aiello V; Cianciolo G; Vicennati V; Tomassetti A; Moschione G; Berti S; Pagotto U; La Manna G
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
    Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
    J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy.
    Dong Y; Shi S; Liu L; Zhou X; Lv J; Zhang H
    Front Med (Lausanne); 2023; 10():1242241. PubMed ID: 37736600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis.
    Lui DTW; Au ICH; Tang EHM; Cheung CL; Lee CH; Woo YC; Wu T; Tan KCB; Wong CKH
    EClinicalMedicine; 2022 Aug; 50():101510. PubMed ID: 35784442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
    Varshney N; Billups SJ; Saseen JJ; Fixen CW
    Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function.
    Sada K; Hidaka S; Kashima J; Morita M; Sada K; Shibata H
    J Diabetes Investig; 2022 Aug; 13(8):1330-1338. PubMed ID: 35322583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease.
    Sugiyama S; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T; Jinnouchi H
    J Clin Med Res; 2020 Nov; 12(11):724-733. PubMed ID: 33224374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report.
    Biancalana E; Ceccarini G; Magno S; Ortenzi V; Giannese D; Santini F; Solini A
    Front Endocrinol (Lausanne); 2023; 14():1172468. PubMed ID: 37274321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice.
    Murashima M; Tanaka T; Kasugai T; Tomonari T; Ide A; Ono M; Mizuno M; Suzuki T; Hamano T
    J Diabetes Investig; 2022 Apr; 13(4):638-646. PubMed ID: 34797947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience.
    Tumminia A; Graziano M; Vinciguerra F; Lomonaco A; Frittita L
    Prim Care Diabetes; 2021 Apr; 15(2):283-288. PubMed ID: 33129749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study.
    Boeckhaus J; Gross O
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
    Rossing P; Anker SD; Filippatos G; Pitt B; Ruilope LM; Birkenfeld AL; McGill JB; Rosas SE; Joseph A; Gebel M; Roberts L; Scheerer MF; Bakris GL; Agarwal R;
    Diabetes Care; 2022 Dec; 45(12):2991-2998. PubMed ID: 35972218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.